BD Shares Rise on FDA OK for MRSA Test, Stock Upgrade | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of Becton Dickinson rose nearly 4 percent today after the firm announced that the US Food and Drug Administration had cleared its GeneOhm StaphSR assay for identifying Staphylococcus aureus and methicillin-resistant S. aureus from patients with positive blood cultures in around two hours.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.